No. of eyes (n) | 22 |
---|---|
PNV eyes | 14 |
Right / Left | 8 / 6 |
Partner eyes | 8 |
Right / Left | 3 / 5 |
No. of patients (n) | 11 |
Gender (m/f) | 7/4 |
Mean age (years) | 64.2 ± 4.0 (range: 60–72) |
Mean follow-up (y) | 1.8 ± 0.4 (1.00–2.00) |
Year 1 | 22 (100%) |
Year 2 | 17 (77.2%) |
Pachychoroid disease stage | |
PNV eyes (n = 14) | |
1 (PPE) | 0 |
2 (CSC) | 0 |
3 (PNV) | 14 (100%) |
4 (PAT1) | 0 |
Partner eyes (n = 8) | |
1 (PPE) | 4 (50%) |
2 (CSC) | 1 (12.5%) |
3 (PNV) | 0 |
4 (PAT1) | 0 |
Macular morphology | |
PNV eyes | |
Subretinal fluid | 14 (100%) |
Intraretinal fluid | 0 |
Flat, irregular PED | 14 (100%) |
CNV | 14 (100%) |
Partner eyes | |
Subretinal fluid | 1 |
Intraretinal fluid | 0 |
Flat, irregular PED | 0 |
CNV | 0 |
Mean Ranibizumab injections | |
PNV eyes | |
Year 1 | 7.0 ± 2.9 (2–11) |
Year 2 | 6.5 ± 3.1 (1–10) |
Partner Eyes | |
Year 1 | 0 |
Year 2 | 0 |